Cargando…

Potent interaction of flavopiridol with MRP1

The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its anti-proliferative characteristic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hooijberg, J H, Broxterman, H J, Scheffer, G L, Vrasdonk, C, Heijn, M, Jong, M C de, Scheper, R J, Lankelma, J, Pinedo, HM
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362861/
https://www.ncbi.nlm.nih.gov/pubmed/10496352
http://dx.doi.org/10.1038/sj.bjc.6690687
_version_ 1782153559509303296
author Hooijberg, J H
Broxterman, H J
Scheffer, G L
Vrasdonk, C
Heijn, M
Jong, M C de
Scheper, R J
Lankelma, J
Pinedo, HM
author_facet Hooijberg, J H
Broxterman, H J
Scheffer, G L
Vrasdonk, C
Heijn, M
Jong, M C de
Scheper, R J
Lankelma, J
Pinedo, HM
author_sort Hooijberg, J H
collection PubMed
description The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its anti-proliferative characteristics, interacts with MRP1 in a potent way. Flavopiridol, as well as other (iso)flavonoids stimulate the ATPase activity of MRP1 in a dose-dependent way at low micromolar concentrations. A new specific monoclonal antibody against MRP1 (MIB6) inhibits the (iso)flavonoid-induced ATPase activity of plasma membrane vesicles prepared from the MRP1 overexpressing cell line GLC(4)/ADR. The accumulation of daunorubicin in GLC(4)/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. However, flavopiridol is the only tested compound that affects the daunorubicin accumulation when present at concentrations below 1 μM. Glycosylated (iso)flavonoids do not affect MRP1-mediated transport or ATPase activity. Finally, MRP1 overexpressing and transfected cells are resistant to flavopiridol, but not to other (iso)flavonoids tested. These findings may be of relevance for the development of anticancer therapies with flavopiridol. © 1999 Cancer Research Campaign
format Text
id pubmed-2362861
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23628612009-09-10 Potent interaction of flavopiridol with MRP1 Hooijberg, J H Broxterman, H J Scheffer, G L Vrasdonk, C Heijn, M Jong, M C de Scheper, R J Lankelma, J Pinedo, HM Br J Cancer Regular Article The multidrug resistance protein 1 (MRP1) is an ATP-dependent transport protein for organic anions, as well as neutral or positively charged anticancer agents. In this study we show that flavopiridol, a synthetic flavonoid currently studied in phase 1 trials for its anti-proliferative characteristics, interacts with MRP1 in a potent way. Flavopiridol, as well as other (iso)flavonoids stimulate the ATPase activity of MRP1 in a dose-dependent way at low micromolar concentrations. A new specific monoclonal antibody against MRP1 (MIB6) inhibits the (iso)flavonoid-induced ATPase activity of plasma membrane vesicles prepared from the MRP1 overexpressing cell line GLC(4)/ADR. The accumulation of daunorubicin in GLC(4)/ADR cells is increased by flavopiridol and by other non-glycosylated (iso)flavonoids that interact with MRP1 ATPase activity. However, flavopiridol is the only tested compound that affects the daunorubicin accumulation when present at concentrations below 1 μM. Glycosylated (iso)flavonoids do not affect MRP1-mediated transport or ATPase activity. Finally, MRP1 overexpressing and transfected cells are resistant to flavopiridol, but not to other (iso)flavonoids tested. These findings may be of relevance for the development of anticancer therapies with flavopiridol. © 1999 Cancer Research Campaign Nature Publishing Group 1999-09 /pmc/articles/PMC2362861/ /pubmed/10496352 http://dx.doi.org/10.1038/sj.bjc.6690687 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Hooijberg, J H
Broxterman, H J
Scheffer, G L
Vrasdonk, C
Heijn, M
Jong, M C de
Scheper, R J
Lankelma, J
Pinedo, HM
Potent interaction of flavopiridol with MRP1
title Potent interaction of flavopiridol with MRP1
title_full Potent interaction of flavopiridol with MRP1
title_fullStr Potent interaction of flavopiridol with MRP1
title_full_unstemmed Potent interaction of flavopiridol with MRP1
title_short Potent interaction of flavopiridol with MRP1
title_sort potent interaction of flavopiridol with mrp1
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362861/
https://www.ncbi.nlm.nih.gov/pubmed/10496352
http://dx.doi.org/10.1038/sj.bjc.6690687
work_keys_str_mv AT hooijbergjh potentinteractionofflavopiridolwithmrp1
AT broxtermanhj potentinteractionofflavopiridolwithmrp1
AT scheffergl potentinteractionofflavopiridolwithmrp1
AT vrasdonkc potentinteractionofflavopiridolwithmrp1
AT heijnm potentinteractionofflavopiridolwithmrp1
AT jongmcde potentinteractionofflavopiridolwithmrp1
AT scheperrj potentinteractionofflavopiridolwithmrp1
AT lankelmaj potentinteractionofflavopiridolwithmrp1
AT pinedohm potentinteractionofflavopiridolwithmrp1